Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

A Phase 2 Study of INCMGA-0012 in Participants with Metastatic Merkel Cell Carcinoma (PODIUM)

General Information

Age Group

Adult

Status

Recruiting

Protocol Number

NCT03599713

Background Information

The purpose of this study is to test the safety and effectiveness of the study drug INCMGA00012 in participants with Metastatic Merkel Cell Carcinoma.

Offered At

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031

A department of Inova Fairfax Hospital

Eligibility Information

  • Participants must be 18 years of age or older
  • Participants must have histologically confirmed MCC with distant metastatic disease as a component of tumor burden and no more than 3 prior systemic treatments, inclusive of systemic adjuvant therapy
  • Additional eligibility in protocol

Ineligibility Information

  • Prior programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy
  • Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders
  • Additional ineligibility in protocol

For more information go to: https://clinicaltrials.gov/ct2/show/NCT03599713